IP Library › Patent Application 11579375
Patent Application
App. No. 11/579,375

Use of Roflumilast for the Prophylaxis or Treatment of Emphysema

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/579,375
Abstract

The invention relates to the use of roflumilast for the prophylaxis of or the treatment of emphysema.

Claims (42)

1 .- 3 . (canceled)

4 . A method for the prophylaxis of or the treatment of emphysema in a patient comprising administering to a patient in need thereof a therapeutically effective amount of roflumilast.

5 . A method for the prophylaxis of emphysema in a patient comprising administering to a patient in need thereof a therapeutically effective amount of roflumilast.

6 . A method for the treatment of emphysema in a patient comprising administering to a patient in need thereof a therapeutically effective amount of roflumilast.

7 . A method for the prevention or reduction of lung desmosine content decrease in a patient comprising administering to a patient in need thereof a therapeutically effective amount of roflumilast.

8 . A method for the treatment of mild emphysema in a patient comprising

(a) determining the amount of desmosine in a patient's urine

(b) comparing the amount of desmosine in the urine of said patient with the amount of desmosine in a healthy subject's urine, and in case the amount of desmosine in the urine of said patient is higher than the amount of desmosine in the urine of said healthy subject,

(c) administering to said patient a therapeutically effective amount of roflumilast.

9 . A method for the prevention or reduction of an increase of the average inter-alveolar distance [mean linear intercept (Lm)] in a patient comprising administering to a patient in need thereof a therapeutically effective amount of roflumilast.

10 .- 13 . (canceled)

14 . The method according to claim 4 , wherein roflumilast represents 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide (ROFLUMILAST).

15 . The method according to claim 4 , wherein roflumilast represents 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxido-pyrid-4-yl)benzamide (ROFLUMILAST-N-Oxide).

16 . The method according to claim 4 , wherein roflumilast represents a pharmaceutically acceptable salt of 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide (ROFLUMILAST).

17 . The method according to claim 4 , wherein roflumilast represents a pharmaceutically acceptable salt of 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxido-pyrid-4-yl)benzamide (ROFLUMILAST-N-Oxide).

18 .- 19 . (canceled)

20 . The method according to claim 14 , wherein the daily therapeutically effective amount of 3-cyclopropylmethoxy-N-(3,5-dichloropyrid-4-yl)benzamide (ROFLUMILAST) for an adult patient is 500 μg.

21 . The method according to claim 15 , wherein the daily therapeutically effective amount of 3-cyclopropylmethoxy-N-(3,5-dichloro-1-oxido-pyrid-4-yl)benzamide (ROFLUMILAST-N-Oxide) for an adult patient is 500 μg.

22 . The method according to claim 5 , wherein roflumilast represents 3-cyclopropylmethoxy-4-difluoro-methoxy-N-(3,5-dichloropyrid-4-yl)benzamide (ROFLUMILAST).

23 . The method according to claim 5 , wherein roflumilast represents 3-cyclopropylmethoxy-4-difluoro-methoxy-N-(3,5-dichloro-1-oxido-pyrid-4-yl)benzamide (ROFLUMILAST-N-Oxide).

24 . The method according to claim 5 , wherein roflumilast represents a pharmaceutically acceptable salt of 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide (ROFLUMILAST).

25 . The method according to claim 5 , wherein roflumilast represents a pharmaceutically acceptable salt of 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxido-pyrid-4-yl)benzamide (ROFLUMILAST-N-Oxide).

26 . The method according to claim 6 , wherein roflumilast represents 3-cyclopropylmethoxy-4-difluoro-methoxy-N-(3,5-dichloropyrid-4-yl)benzamide (ROFLUMILAST).

27 . The method according to claim 6 , wherein roflumilast represents 3-cyclopropylmethoxy-4-difluoro-methoxy-N-(3,5-dichloro-1-oxido-pyrid-4-yl)benzamide (ROFLUMILAST-N-Oxide).

28 . The method according to claim 6 , wherein roflumilast represents a pharmaceutically acceptable salt of 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide (ROFLUMILAST).

29 . The method according to claim 6 , wherein roflumilast represents a pharmaceutically acceptable salt of 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxido-pyrid-4-yl)benzamide (ROFLUMILAST-N-Oxide).

30 . The method according to claim 7 , wherein roflumilast represents 3-cyclopropylmethoxy-4-difluoro-methoxy-N-(3,5-dichloropyrid-4-yl)benzamide (ROFLUMILAST).

31 . The method according to claim 7 , wherein roflumilast represents 3-cyclopropylmethoxy-4-difluoro-methoxy-N-(3,5-dichloro-1-oxido-pyrid-4-yl)benzamide (ROFLUMILAST-N-Oxide).

32 . The method according to claim 7 , wherein roflumilast represents a pharmaceutically acceptable salt of 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide (ROFLUMILAST).

33 . The method according to claim 7 , wherein roflumilast represents a pharmaceutically acceptable salt of 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxido-pyrid-4-yl)benzamide (ROFLUMILAST-N-Oxide).

34 . The method according to claim 8 , wherein roflumilast represents 3-cyclopropylmethoxy-4-difluoro-methoxy-N-(3,5-dichloropyrid-4-yl)benzamide (ROFLUMILAST).

35 . The method according to claim 8 , wherein roflumilast represents 3-cyclopropylmethoxy-4-difluoro-methoxy-N-(3,5-dichloro-1-oxido-pyrid-4-yl)benzamide (ROFLUMILAST-N-Oxide).

36 . The method according to claim 8 , wherein roflumilast represents a pharmaceutically acceptable salt of 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide (ROFLUMILAST).

37 . The method according to claim 8 , wherein roflumilast represents a pharmaceutically acceptable salt of 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxido-pyrid-4-yl)benzamide (ROFLUMILAST-N-Oxide).

38 . The method according to claim 9 , wherein roflumilast represents 3-cyclopropylmethoxy-4-difluoro-methoxy-N-(3,5-dichloropyrid-4-yl)benzamide (ROFLUMILAST).

39 . The method according to claim 9 , wherein roflumilast represents 3-cyclopropylmethoxy-4-difluoro-methoxy-N-(3,5-dichloro-1-oxido-pyrid-4-yl)benzamide (ROFLUMILAST-N-Oxide).

40 . The method according to claim 9 , wherein roflumilast represents a pharmaceutically acceptable salt of 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide (ROFLUMILAST).

41 . The method according to claim 9 , wherein roflumilast represents a pharmaceutically acceptable salt of 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxido-pyrid-4-yl)benzamide (ROFLUMILAST-N-Oxide).

42 . The method according to claim 15 , wherein the daily therapeutically effective amount of 3-cyclopropylmethoxy-N-(3,5-dichloropyrid-4-yl)benzamide (ROFLUMILAST) for an adult patient is 500 μg.

43 . The method according to claim 16 , wherein the daily therapeutically effective amount of 3-cyclopropylmethoxy-N-(3,5-dichloropyrid-4-yl)benzamide (ROFLUMILAST) for an adult patient is 500 μg.

44 . The method according to claim 16 , wherein the daily therapeutically effective amount of 3-cyclopropylmethoxy-N-(3,5-dichloro-1-oxido-pyrid-4-yl)benzamide (ROFLUMILAST-N-Oxide) for an adult patient is 500 μg.

45 . The method according to claim 17 , wherein the daily therapeutically effective amount of 3-cyclopropylmethoxy-N-(3,5-dichloro-1-oxido-pyrid-4-yl)benzamide (ROFLUMILAST-N-Oxide) for an adult patient is 500 μg.

Assignments (2)
CHANGE OF NAME Recorded Sep 4, 2007
From: ALTANA PHARMA AG
To: NYCOMED GMBH
Reel/Frame 019783/0625 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2006
From: WOLLIN, STEFAN-LUTZ; BEUME, ROLF; LUNGARELLA, GIUSEPPE; MARTORANA, PIERO
To: ALTANA PHARMA AG
Reel/Frame 018592/0955 →